comparemela.com

Latest Breaking News On - Jim fickenscher - Page 1 : comparemela.com

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights - Zynerba

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Zynerba

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan. | March 29, 2023

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.